MRI scans are strong diagnostics with high-definition images of what lies inside a body. Strong magnetic fields require precaution, as brought out by an instance where a young woman suffered very serious injuries due to an oversight in a metallic core within a silicone sex toy that she happened to have before the MRI scan. This makes a stark reminder about the potentially deadly consequences of missing metal objects when such procedures are being performed. In April 2023, a 23-year-old woman went into an MRI with a silicone plug containing a metal core that was not known.
She thought that the item is made entirely out of silicone according to the advertising. However, the strong magnetic field of the MRI machine interacted with the hidden metal, dragging the object through her body and causing excruciating pain. According to reports from the U.S. Food and Drug Administration (FDA), the scene was harrowing, with the woman screaming in agony and requiring immediate hospitalization. Despite pre-scan screenings, which are routine prior to a scan, the patient did not inform the facility that the object existed because he presumed it was purely non-metallic. This caused serious injuries that led to the patient's law suit against the manufacturer for deceitful misrepresentations of material content.
MRI machines employ magnets between 0.5 to 3 Tesla (T). This is thousands of times stronger than the Earth's magnetic field. The tremendous force causes ferromagnetic materials, like iron and nickel, to be magnetized quickly and become strongly attracted toward the magnet. Objects as small as hairpins or paper clips will accelerate at 40 miles per hour inside the magnetic field.
The force can lead to catastrophic injuries in items lodged within the body, such as metallic implants or foreign objects. Metallic cores within devices, like pacemakers or intrauterine devices, must be disclosed to radiologists to prevent such complications.
On these claims, Dr. Adam Taylor, a specialist in human anatomy, weighed his words in a international health website and added that the distance away and mass of this object would increase its velocity towards that of sound, "The acceleration would be phenomenal, but with a metallic core, it can't go anywhere near supersonic speeds. As for the size, the magnetic acceleration to the internal soft tissues would ensure that there could be severe intracranial trauma."
The injuries inflicted in this case likely involved damage to major blood vessels, nerves, or organs, highlighting the devastating impact of even minor oversight during an MRI scan.
This is not an isolated case. There are documented cases of metallic objects causing serious damage during MRI scans with a 65-year-old man with schizophrenia swallowed metal objects, including sockets and a hinge pin. The powerful magnetic field during an MRI scan caused the objects to rupture his stomach, resulting in serious injuries.
A toddler who ingested 11 small magnets perforated his bowel while undergoing a scan, making his case unique. In another deadly but extremely rare incident, there have been people who hide a firearm on themselves during MRI procedures. Magnetic attraction can trigger a discharge in a weapon and has led to some fatal injuries.
These cases emphasize the very strong need for adequate screening and patient education prior to an MRI.
Medical professionals have been trained to avoid risks. This is by properly screening a patient for metallic objects. In general, most pre-scan protocols include:
The case emphasizes the importance of product labeling by manufacturers, especially those products that are likely to unintentionally cause harm to health. The patient's assumption that her device was 100% silicone points to a larger problem in consumer markets with misinformation.
It also reminds the patients to report any possible dangers to the medical professionals, no matter how the objects look non-metallic. In sensitive cases, patients can request private discussions with healthcare providers to ensure safety without discomfort.
In the end, it is a joint effort from manufacturers, healthcare professionals, and patients that can prevent such tragedies. Manufacturers must ensure truthful marketing, while healthcare providers should educate patients about the dangers of metal objects in MRI settings. For patients, understanding the risks and actively participating in pre-scan disclosures can be lifesaving.
This young woman's experience is a sobering example of the unforeseen dangers posed by MRI machines when precautions are overlooked. It serves as a wake-up call to address gaps in patient awareness, medical protocols, and product transparency. By learning from this incident, the medical community and the public can work together to ensure MRI scans remain a safe and effective diagnostic tool.
Credit: AI generated image
The hantavirus outbreak may no longer be confined to the luxury Dutch cruise ship MV Hondius, with health officials now assessing the possibility of wider exposure. Officials at the US Centers for Disease Control and Prevention (CDC) said that although no cases have been reported in the US so far, the agency is monitoring 41 people for possible exposure.
The 41 includes the 18 people evacuated from the hantavirus-hit ship from Spain’s Canary Islands.
Notably, of the 18 passengers evacuated, two were carried in the plane's biocontainment units out of an abundance of caution — one who tested positive and another considered a suspected case. They were quarantined at a special facility in Nebraska. The remaining 16 are being quarantined in Omaha and Atlanta.
Speaking to CNN from a biocontainment unit at the University of Nebraska Medical Center in Omaha, Dr. Stephen Kornfeld of Oregon said he “feels wonderful” and is not experiencing symptoms.
Spanish officials confirmed that after initially testing positive for hantavirus, Dr. Kornfeld has since tested negative twice for the disease, meaning no Americans currently have the illness, Forbes reported.
CDC Monitoring More People
However, an additional 16 people are being monitored by the CDC.
The new individuals were not on the cruise ship but were passengers on an April 25 flight to Johannesburg and were exposed to someone known to have been infected, said Dr. David Fitter, who is leading the CDC response to the outbreak, according to The New York Times.
Also read: Shocking Study Finds Andes Hantavirus Could Linger In Semen For Years, Pose Transmission Risk
Seven other passengers from the cruise ship had disembarked on April 24 in St. Helena, an island in the Atlantic Ocean, returned to the US on commercial flights, and are being monitored by state health departments.
As of May 14, there were no confirmed hantavirus cases in the United States, Dr. Fitter said.
“Our job is to ensure that we are monitoring and in contact with anybody that might have been on the flight this person had taken,” Dr. Fitter told reporters. The agency is “monitoring all Americans that potentially would have been exposed, whether in the US or abroad, and we have been in contact with them,” he said.
According to the World Health Organization (WHO), 11 people have been affected by the rat-borne virus so far, of whom three have died.
A Dutch couple is believed to have first been exposed to the virus while visiting a birdwatching site in Argentina.
The WHO has confirmed that the Andes strain of hantavirus — the only strain known to spread from person to person — is behind the outbreak.
While all passengers onboard the cruise have been taken care of by health authorities, the virus’ long incubation period remains a serious concern. This means that even asymptomatic individuals could potentially become infectious 6-8 weeks later.
The WHO recommends that people exposed to hantavirus should be:
Credit: iStock
The UK is witnessing yet another outbreak of meningitis, with one college student dead and two others infected in Berkshire, according to the UK Health Security Agency (UKHSA).
According to the agency, close contacts of those affected are being offered antibiotics as a precautionary measure.
Also Read: Why Rebranding PCOS As PMOS Could Mark A New Era In Women’s Health
While stressing that the risk to the wider public remains low, the UKHSA confirmed that one case has been identified as Meningitis B (MenB), while further testing is ongoing.
The latest infections come after a small number of meningitis B cases were reported in the Weymouth region in April, followed by a major outbreak in Kent in March that affected more than 30 people and led to the deaths of a sixth-form pupil and a university student.
The young person who died attended The Henley College, according to a local GP surgery.
Authorities are reportedly sharing information about the infection with students and parents at affected schools. The other two cases are believed to be linked to schools in the Reading area. But the officials are yet to disclose the exact link.
Health officials said close contacts of the infected individuals are being offered antibiotics as a precaution.
Read More: Hantavirus Outbreak: Critically Ill French Patient On Artificial Lung Support
GP surgery, the Hart Surgery, based in Henley-on-Thames, stated that it was in contact with the UKHSA due to the college’s location, adding that the agency was “actively contacting those who may be at risk due to a close association with the student involved.”
However, it said anyone whom the UKHSA has not contacted does not require treatment, and students and staff can continue attending the sixth-form college as usual.
“The number of confirmed cases is very low, so there are currently no plans for a local emergency meningitis vaccination programme,” it added.
Also read: UK Reports Meningitis Outbreak Among School Children: All You Need To Know
Meningitis is a serious medical condition that affects the protective membranes covering the brain and spinal cord, known as the meninges. Fever is often considered one of the classic symptoms, although it may not always be present.
Understanding the symptoms, causes, and treatment options is important for early diagnosis and timely medical care.
“Anyone can get meningitis, and around 300 to 400 cases of meningococcal disease are diagnosed in England every year. It is most common in babies, young children, teenagers, and young adults," said Dr Rachel Mearkle, a consultant in health protection at the UKHSA.
“It needs to be treated quickly, so it is important to know the signs and symptoms. They can appear in any order and may not all be present, so seek rapid medical attention if there is ever any concern," she added.
The expert noted that "meningococcal meningitis requires very close contact to spread, and large outbreaks such as the one recently seen in Kent are thankfully rare."
“Meningococcal disease does not spread easily, and the risk to the wider public remains low.”
Health officials urged the public to remain alert to the warning signs of meningococcal meningitis. Common symptoms include:
“If the disease is suspected, immediate medical attention should be sought, as it can progress rapidly,” the officials said. While antibiotics provide the quickest short-term protection, vaccines offer longer-term protection.
Credit: Canva
Pancreatic cancer has long been one of the toughest challenges in oncology. With a five-year survival rate hovering around 13 per cent and recurrence rates approaching 80 per cent after treatment, the odds have historically been stacked against patients.
However, an experimental drug called daraxonrasib, developed by the US-based late-stage clinical oncology company Revolution Medicines, has shown promise in improving survival rates in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
“For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and improve quality of life,” said Brian M. Wolpin, professor of medicine at Harvard Medical School, and principal investigator for the trial.
Wolpin noted that the study “indicates that daraxonrasib provides a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment, typically chemotherapy.”
Daraxonrasib is a once-daily oral pill that demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) compared with standard intravenous chemotherapy.
Daraxonrasib, described as a multi-selective inhibitor of RAS(ON) proteins, is the first investigational drug in a new class of RAS inhibitors designed to target a broad spectrum of cancer-causing RAS mutations.
In the clinical trial, daraxonrasib showed a median overall survival of 13.2 months, compared with 6.7 months for chemotherapy.
The drug was generally well tolerated and showed a manageable safety profile, with no new safety concerns identified.
Daraxonrasib works by blocking KRAS signalling proteins that drive tumor growth.
Pancreatic cancer is considered one of the most RAS-addicted cancers, with more than 90 per cent of patients carrying tumours driven by RAS protein mutations.
Also read: Former US Senator Ben Sasse Opens Up About Battle With Terminal Stage 4 Pancreatic Cancer
The controlled Phase 3 clinical trial evaluated daraxonrasib in patients with previously treated metastatic PDAC.
The trial included patients with pancreatic tumours carrying a wide range of RAS variants, as well as patients without identified RAS mutations.
The results showed that daraxonrasib significantly improved overall survival in patients with previously treated metastatic pancreatic cancer.
Similar RAS-targeting drugs are now being developed by other companies for pancreatic, lung, and colon cancers.
“It’s the beginning, not the end,” said Elizabeth Jaffee in comments to The New York Times.
According to the company, “Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.”
Prior studies with daraxonrasib have shown that rash is the most common side effect, with mouth sores, diarrhea, nausea, and vomiting also common.
Also read: India Gets Its First Alzheimer’s Drug: Know All About Eli Lilly’s Lormalzi
Based on the first interim analysis, all progression-free survival and overall survival results are now considered final.
Revolution Medicines said it plans to submit the data to global regulators, including the US Food and Drug Administration (FDA), as part of a future New Drug Application under a Commissioner’s National Priority Voucher.
The findings are also expected to be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Pancreatic cancer typically begins in the ducts of the organ and can rapidly spread from there to the rest of the organ. Early-stage pancreatic tumors do not show up on imaging tests, making this version of the disease difficult to diagnose until it infects other organs.
The prevention and early detection remain vital.
Experts warn that pancreatic cancer often masquerades as common ailments, delaying diagnosis. Here are some early symptoms that should never be ignored:
© 2024 Bennett, Coleman & Company Limited